Please login to the form below

Not currently logged in

J&J files rare blood disorder drug siltuximab in US and EU

Orphan drug to be assessed for use in the treatment of multicentric Castleman disease

Johnson & Johnson headquarters

Johnson & Johnson (J&J) has filed for approval of its investigational drug siltuximab in both the EU and US as a treatment for a rare blood disorder.

The group's pharma subsidiary Janssen has submitted market applications to both the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the use of siltuximab in patients with multicentric Castleman disease (MCD) who do not have HIV or human herpes virus-8.

The condition is a rare disease that causes white blood cells to over-produce, leading to the enlargement of lymph nodes.

According to J&J, this can cause several symptoms, such as fever, nausea and nerve damage, and weaken a person's immune system, making it hard to fight infection.

There is also a unicentric form of the condition, which affects only a single area or group of lymph node and can be treated with surgery.

However, the multicentric form of the condition affects lymphoid tissue around the body and is much harder to treat, with current therapies including corticosteroids, chemotherapy and immunotherapy.

If approved, siltuximab would be the first medicine approved in the US or Europe specifically for MCD and would mark a major step in treatment for the rare condition.

“As a rare disease with a small patient population, MCD is an area of significant unmet need,” said Dr Peter Lebowitz, global oncology therapeutic area head, Janssen.

He explained that siltuximab works by targeting interleukin-6, which is a cytokine, or cell signalling molecule, that is thought to be the critical driver of MCD.

“By focusing on core biologic mechanisms, we now have the potential of helping patients with a condition that is challenging to treat,” added Dr Lebowitz.

The submissions are based primarily on data from the randomised MCD2001 study, which compared siltuximab plus best supportive care with placebo plus best supportive care.

Results from this study have been submitted for presentation at a medical meeting later this year, said J&J.

Due to the rarity of MCD, siltuximab has orphan status in both the EU and the US, meaning J&J has regulatory incentives, such as tax breaks and extra support, to develop the drug.

Article by
Thomas Meek

5th September 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...